{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:59:04Z","timestamp":1761893944584,"version":"3.30.2"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,5,4]],"date-time":"2004-05-04T00:00:00Z","timestamp":1083628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold>Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. We have investigated the common and rare side\u2010effects, especially analysing peripheral neuropathy, in order to optimise the thalidomide dose for minimizing this harmful side\u2010effect.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>Fifty\u2010nine patients were treated with thalidomide alone or combined with oral melphalan. The median age was 69\u2003yr. The initial dose of thalidomide was 100\u2003mg\/day increasing weekly by 100\u2003mg increments until a maximum dose of 400\u2003mg was attained. Melphalan was administered at a dose of 0.20\u2003mg\/kg\/d for 4\u2003d every 28\u2003d.<\/jats:p><jats:p><jats:bold>Results and conclusions:\u2002<\/jats:bold>Nearly one\u2010fourth of patients discontinued thalidomide because of toxicity. Constipation (71%), somnolence (36%) and fatigue (20%) were the most common side\u2010effects and they were not dose dependent. Peripheral neuropathy occurred in 39% of patients and a thalidomide median daily dose of more than 150\u2003mg was significantly associated with higher frequency and actuarial risk of peripheral neuropathy without improving the response rate. Deep venous thrombosis was observed in 7% of patients and other side\u2010effects were rare. In patients with advanced multiple myeloma we found that a thalidomide daily dose of 150\u2003mg minimizes peripheral neuropathy without jeopardizing response and survival.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2004.00238.x","type":"journal-article","created":{"date-parts":[[2004,5,4]],"date-time":"2004-05-04T16:42:23Z","timestamp":1083688943000},"page":"403-409","source":"Crossref","is-referenced-by-count":35,"title":["Common and rare side\u2010effects of low\u2010dose thalidomide in multiple myeloma: focus on the dose\u2010minimizing peripheral neuropathy"],"prefix":"10.1111","volume":"72","author":[{"given":"Massimo","family":"Offidani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Corvatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Malerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marino","family":"Brunori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Catarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Candela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Rupoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,4]]},"reference":[{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"e_1_2_14_3_2","first-page":"163a","article-title":"Low dose thalidomide alone and in combination: long term follow\u2010up","volume":"98","author":"Durie BGM","year":"2001","journal-title":"Blood"},{"key":"e_1_2_14_4_2","first-page":"162a","article-title":"Intermediate dose thalidomide (200\u2003mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma","volume":"98","author":"Wechalekar AD","year":"2001","journal-title":"Blood"},{"issue":"1","key":"e_1_2_14_5_2","first-page":"167a","article-title":"Thalidomide with dexamethasone for resistant multiple myeloma","volume":"96","author":"Weber DM","year":"2000","journal-title":"Blood"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011132808904"},{"key":"e_1_2_14_7_2","first-page":"163a","article-title":"Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractory multiple myeloma","volume":"98","author":"Tosi P","year":"2001","journal-title":"Blood"},{"key":"e_1_2_14_8_2","first-page":"399","article-title":"Low\u2010dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo A","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_14_9_2","first-page":"164a","article-title":"Oral hyperfractionated cyclophosphamide and intermittent thalidomide\u2010dexamethasone for previously treated patients with multiple myeloma","volume":"98","author":"Dimopoulos M","year":"2001","journal-title":"Blood"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3846"},{"key":"e_1_2_14_11_2","first-page":"403a","article-title":"Doxil(D), vincristine (V), decadron (d) and thalidomide (T) (DVd\u2010T) for relapsed\/refractory multiple myeloma (RMM)","volume":"100","author":"Hussein MA","year":"2002","journal-title":"Blood"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04473.x"},{"issue":"1","key":"e_1_2_14_13_2","first-page":"66","article-title":"A study of the safety and efficacy of oral melphalan, prednisolone and thalidomide (MPT) in the treatment of multiple myeloma: a UK Myeloma Forum Pilot Study","volume":"117","author":"Oakervee H","year":"2002","journal-title":"Br J Haematol"},{"key":"e_1_2_14_14_2","first-page":"402a","article-title":"Thalidomide combined with vincristine, adriamycin and dexamethasone (T\u2010VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting","volume":"100","author":"Oakervee H","year":"2002","journal-title":"Blood"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:4:219"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19502.x"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_14_20_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc Series B"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1985.tb02323.x"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_14_23_2","first-page":"408","article-title":"Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma","volume":"87","author":"Tosi P","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.34"},{"key":"e_1_2_14_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf258"},{"key":"e_1_2_14_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.31.6.543"},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000037480.59194.85"},{"key":"e_1_2_14_28_2","first-page":"3377","article-title":"Dose\u2010dependent effect of thalidomide on overall survival in relapsed multiple myeloma","volume":"8","author":"Neben K","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_2_14_29_2","first-page":"123a","article-title":"Chemoangiotherapy with DT\u2010PACE for previously treated multiple myeloma (MM)","volume":"94","author":"Munshi N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_14_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1062"},{"key":"e_1_2_14_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg095"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00238.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2004.00238.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2004.00238.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:49:04Z","timestamp":1734349744000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2004.00238.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,4]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1111\/j.1600-0609.2004.00238.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00238.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2004,5,4]]}}}